In Vivo Pharmacodynamic Evaluation of Bleomycin Induced Pulmonary Fibrosis Mouse Model (CAT#: STEM-AE-0688-LGZ)

Introduction

Pulmonary fibrosis is a type of end-stage of interstitial lung disease. A variety of factors, including toxic, autoimmune, drug-induced, infectious, or traumatic injuries can cause pulmonary fibrosis. It is characterized by fibroblast proliferation, extracellular matrix aggregation, inflammatory damage and tissue structure destruction.
Bleomycin (BLM) is one of the most widely used drugs for inducing lung fibrosis in animals. Due to its ability to provoke a histologic lung pattern similar to that described in patients undergoing chemotherapy. BLM is thought to exert its cytotoxic effect by cleaving DNA, inducing an inflammatory response and increasing epithelial apoptosisdose, thus stimulating lung injury and resultant fibrosis.